Relevant conflicts of interest/financial disclosures: The educational grant from UCB Pharma funding this research contributed to the salaries of Kitty K. Wong and Jane E. Alty during the conduct of the study.
Version of Record online: 29 APR 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 8, pages 1552–1555, July 2011
How to Cite
Wong, K. K., Alty, J. E., Goy, A. G., Raghav, S., Reutens, D. C. and Kempster, P. A. (2011), A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. Mov. Disord., 26: 1552–1555. doi: 10.1002/mds.23687
The research was supported by an educational grant from UCB Pharma.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue online: 21 JUL 2011
- Version of Record online: 29 APR 2011
- Manuscript Accepted: 28 JAN 2011
- Manuscript Revised: 4 JAN 2011
- Manuscript Received: 19 OCT 2010
- Parkinson's disease;
This randomized double blind, placebo-controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease.
Sixteen participants with levodopa-induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments scored by the Goetz method and hourly Unified Parkinson's Disease Rating Scale motor subscale scoring were conducted on 1 day at the end of each treatment period.
Dyskinesia was slightly less on placebo (P = .26). Patient diary records also showed less dyskinesia on placebo (P = .10). Parkinsonism was a little worse on levetiracetam, at borderline statistical significance (P = .05).
Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties. © 2011 Movement Disorder Society